Lundbeck Takes A Singular View Toward Tackling Challenging CNS Disorders
The Danish drug maker has focused R&D on four CNS specialties under its new CEO and is moving forward two late-stage programs for symptoms of Alzheimer’s disease. Exec VP-Lundbeck Research, USA Stevin Zorn discusses the firm’s R&D strategy in an interview.
You may also be interested in...
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.